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1. Introduction
Hepatocellular carcinoma (HCC) is often diagnosed after the tumor manifests clinical signs
and symptoms. Early diagnosis is usually performed thanks to HCC screening programs for
patients affected by liver cirrhosis or chronic viral hepatopathies using ultrasound and serum
alfa-fetoprotien. In most HCC cases, clinical signs and symptoms of this tumor may occur
several months after development, when therapy can not be curative, given the advanced
tumor stage and underlying liver disease, which preclude curative options, such as ablation,
resection, or liver transplantation.
Clinical features of HCC are often similar to those caused by the underlying hepatic disease.
It is very hard for physicians to distinguish signs and symptoms of HCC in contests charac‐
terized by an advanced liver disease. Advanced liver cancer can be responsible for accelerated
liver functions deterioration caused by the intrahepatic tumor growth.
In this chapter, we review the clinical signs and symptoms induced by advanced carcinoma.
We also discuss particular clinical scenarios caused by metastases and paraneoplastic syn‐
dromes, sometimes described case reports in literature.
2. Non-specific signs and symptoms
Non-specific systemic signs and symptoms as asthenia, anorexia, weight loss, and nausea, are
often present in patients with HCC (table 1). HCC should be suspected with the onset of these
clinical features in patients at risk for this tumor.
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2.1. Clinical aspects of cirrhosis
Clinical signs and symptoms of hepatic cirrhosis that is often present in patients with HCC,
usually mask the presence of an underlying early hepatocellular carcinoma [1]. Symptoms and
signs of cirrhosis are often the only expression of the disease. Because of this, patients affected
by HCC usually present at an advanced stage of the disease with clinical signs as jaundice,
ascites, peripheral oedemas, neurologic manifestations of hepatic encephalopathy, bleeding,
or infections. Other signs of hepatic cirrhosis include gynecomastia, palmar erythema, spider
angiomas, axillary or chest hair loss, hypogonadism (testicular atrophy, loss of libido).
A large HCC can worsen the underlying hepatic disease, therefore in case of clinical worsening
of a cirrhotic patient, onset of a HCC should be suspected.
2.2. Hepatomegaly
Hepatomegaly can be an expression of the tumor mass,(table 1) [1,2]. In case of HCC, the
palpable edge of the liver is more often irregular, hard, with nodular consistency.
Hepatomegaly is more often present in patients without advanced cirrhosis [2]. In case of large
tumors, the mass can cause asymmetry of the abdomen [3]. The costal margin can be deformed
and the profile of lower ribs can be asymmetric. The right hemi-diaphragm can be elevated.
This alteration of diaphragm profile can be asymptomatic or can cause mild respiratory
symptoms. With thorax percussion is possible to detect an area of dullness, while trough
auscultation is possible not to hear the vescicular murmur in case of elevation of diaphragm.
HCC can also cause a pleural effusion. All these clinical aspects are difficult to be differentiated
from signs and symptoms of the underlying chronic liver disease: Right diaphragm elevation
is possible in case of hepatopathy not associated to HCC and pleural effusion can be the
expression of an ascending ascitic fluid or of the anasarca state caused by cirrhosis and
hypoalbuminemia.
2.3. Vascular bruit
Trough auscultation of the abdomen, an arterial bruit can be heard in patients affected by HCC.
This bruit is typically heard throughout the liver and it is described to have different charac‐
teristic from other vascular abdominal auscultatory findings. In fact, usually, arterial bruit
caused by abdominal aortic aneurysm or by renal artery stenosis are soft and short. Arterial
bruit caused by HCC is usually a hard bruit and it is more prolonged than those caused by
other conditions. This clinical sign is thought to be caused by the presence of an arteriovenous
fistula in the context of the tumor [4], suggesting the presence of a highly vascularized HCC [5].
3. Abdominal pain, portal vein thrombosis, rupture of HCC
A frequent manifestation of onset of HCC is abdominal pain. The pain is usually mild, located
in right hypochondrium and it can radiate to the right shoulder. Prior reports suggested that
Hepatocellular Carcinoma - Future Outlook198
in black South African patients, abdominal pain is frequent in 95% of cases while it is referred
by 46%, 51% and 38% of Japanese, Chinese and Italian patients, respectively (table 1).
Abdominal pain is more frequent in non cirrhotic patients, and in case of portal thrombosis [1].
Portal vein thrombosis has been found in (14-44%) of autopsies of patients with HCC [6,7].
Patients with both cirrhosis and hepatic carcinoma have the highest risk to develop portal vein
thrombosis [6]. Portal vein thrombosis is reported to be diagnosed during investigation for
acute abdominal pain in 18% of cases in cirrhotic patients [8].
Other clinical manifestations of portal vein thrombosis and/or portal hypertension are
hematemesis from rupture of esophageal varices, nausea, vomiting, anorexia, weight loss,
diarrhea. Splenomegaly has been reported to be present in 75-100% of patients with portal vein
thrombosis [9]. Bleeding from esophageal varices or from portal hypertensive gastropathy is
the most common presenting symptom of portal vein thrombosis in cirrhotic patients [8,10].
In 43% of cases of Portal vein thrombosis in cirrhotic patients, diagnosis is done during a
routine echo-Doppler examination [8].
If a cirrhotic patient present an acute pain, then bleeding from rupture of tumor should be
suspected. HCC rupture causes a severe and sudden pain, and the patient can present the
clinical features of an acute abdomen, with rebound and tenderness during physician palpa‐
tion and an abdominal involuntary defense contraction. A hypovolemic state and signs and
symptoms of acute anemia can be present. Clinical features of chronic anemia can be present
in case of slow blood loss from HCC.
HCC rupture has been reported to be a rare condition in Western countries, occurring only in
3% of Italian patients [11], while spontaneous hemoperitoneum is more frequent in Sub-
Saharian Africa and in Southeast Asia, being present in 10% of patients at presentation [12].
Usually,HCC tumors bleedings are spontaneous, but in rare cases, they can be caused by
external causes. The protrusion of HCC beyond the liver surface seems to be an important risk
factor for HCC rupture [13]: hemorrhages occur more easily and can also be caused by slight
external forces. So HCC rupture can be caused by abdominal traumas [14],vigorous muscular
exertion, or rarely after forceful physician’s palpation [15].
HCC rupture is also a rare complication of therapeutic procedures on HCC. For example after
transcatheter arterial chemoembolization (TACE), HCC rupture occurs in less than 1% of
patients [16].
The drainage of hematic peritoneal liquid in patient with acute abdominal pain can suggest
the presence of a ruptured HCC, not being specific for this condition.
3.1. Gastrointestinal bleeding
A particular manifestation of HCC can be a bleeding from esophageal varices. This presenta‐
tion is not frequent, occurring as first clinical sign only in 1%-8% of cases of HCC [17,18]
(table1). Variceal bleeding is caused by higher pressure in portal district which in turn can be
caused by tumor invasion of this venous system and portal hypertension [17]. This portal
invasion can be detected radiologically in 44-57% [17,18] of cases of variceal bleeding as
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presenting clinical manifestation of HCC. If variceal bleeding can be related with portal venous
system invasion suggesting an advanced neoplastic disease, it does not seem to exist a
relationship between this kind of clinical presentation and the size of the underlying tumor.
Bleeding from esophageal varices is obviously a more frequent clinical presentation of HCC
in patients with more advanced liver cirrhosis [18] and high degree of portal hypertension.
However, HCC can present with variceal bleeding also in patients without a known history
of hepatopathy [17].
Variceal bleeding can present with melena or hematemesis. Bleeding can be massive, leading
to hypovolemic state and it is one of the known triggers of cirrhotic encephalopathy so that
tremors, confusion till to coma, can be present in these patients too. Also infections can be
caused by gastrointestinal bleeding in cirrhotic patients (22% of cases) [19], therefore, clinical
signs and symptoms of an abdominal infections can be present.
Additionally, 50 % of causes of gastrointestinal hemorrhages are represented by hypertensive
gastropathy, peptic ulcer and direct tumoral invasion of digestive tract [20,21].
3.2. Jaundice
Jaundice is a frequent sign of presentation of HCC. Some studies indicated that it is present at
the diagnosis of HCC in 28% of African patients, but less frequent in Chinese, Japanese or
European countries (table1).
Different pathologic conditions linked to HCC can explain the onset of jaundice. Jaundice can
be expression of hepatic failure, due to extensive tumor infiltration of a cirrhotic liver or by
worsening of the underlying hepatitis that can occur in presence of HCC. [22].
In other cases, jaundice result from obstruction of bile ducts by HCC. Clinical manifestation
are those of typical cholestatic syndrome. In these cases jaundice is usually accompanied by
itchiness, caused by elevation of serum level of bile acids, hypocolic stool and dark urine. All
these symptoms can be presents also in the underlying liver disease, not being specific for
biliary tract invasion.
The neoplastic obstruction can occur due to intraluminal biliary obstruction, extraluminal
neoplastic compression or clot formation secondary to hemobilia caused by tumor invasion of
biliary tree [23]. The presence of an intraluminal free-floating tumor fragment in the extrahe‐
patic biliary tree may show an intermittent jaundice that can be associated with colicky pain
[24]. Also in case of hemobilia a colicky pain can be present [5].
3.3. Fever
Fever of Unknown Origin can be a way of presentation of HCC [25,26]. It can be intermittent,
and usually is accompanied by leukocytosis. Imaging studies are often necessary to differen‐
tiate an HCC from a liver abscess. Fever occur more frequently in patients with massive HCC
and in non cirrhotic individuals [1].
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3.4. Caval invasion
If HCC invades the inferior vena cava, signs and symptoms of venous insufficiency can appear.
In this case relevant pitting edema can appear, usually bilaterally, affecting both inferior limbs,
from the inguinal region. The invasion of the venous district, can worsen ascites and hepato‐
megaly [24].
Caval tumor thrombus can extend to the right atrium, causing dyspnea and heart failure [27].
When a patient presents signs and symptoms of right heart failure, such as jugular turgor,
dyspnea, new onset of inferior limbs edema and worsening of hepatic insufficiency, heart
tumoral invasion should always be suspected [28]. Anyway atrial invasion is reported to be
also asymptomatic [29]. Pulmonary embolization by venous invasion is a rare, but reported
primary manifestation of HCC [30].
4. Age differences in presentation
Patient’s age can influence the clinical presentation of HCC. Signs and symptoms at presen‐
tation of HCC described in patients affected by hepatitis B are significantly different in patients
younger and older than 40 years. Younger patients present more often with pain, hepatome‐
galy and ruptured HCC. Older patient present more often with ankle oedema and ascites. This
is explained by the fact that in patients affected by viral hepatitis, advanced cirrhosis is more
frequent in the older ones [2]. In younger patients it is more difficult that cirrhosis masks
clinical aspect caused by HCC.
Clinical signs and symptoms in different geographic regions (%)
Black African Japan China Europe (Italy)
Asymtomatic - - 29,9 38
Abdominal pain 95 46 51 38
Ascites 51 27 18 12
Palpable mass 92 23 5 -
Hepatomegaly - - 54 90
Ankle Edema - 17 14 -
Jaundice 28 17 9 14
Fever 35 17 2 12
Diarrhea - - 1 3
Hemoperitoneum - 7 3 3
Variceal Bleeding 2 8 - 4
Table 1. [1,2,11,24]
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5. Extrahepatic metastases
Metastases from HCC, spread through lymphatic or hematic system, are more frequently
placed in abdominal and thoracic lymph nodes, lung, bones, adrenal glands. Less frequent
sites of metastases are brain, spleen and breast [31]. Rarely metastases can also be detected in
digestive tube, pancreas, seminal vesicle and bladder [32].
When HCC is diagnosed, extrahepatic metastases, are present in more or less 40% of cases,
[32,33] and several signs and symptoms can be caused by this condition. Sometimes signs and
symptoms caused by metastases are the only clinical manifestation of HCC [34]. Regional
lymph nodes are affected in up to 60% of metastatic HCC, while distant lymphatic stations are
involved only in 12% of these cases [32]. The frequencies of metastases in different sites are
reported in (Table 2).
Pain and pathologic fractures can be caused by osteolytic metastases. Severe pain is present in
90 % of patients with bone metastases [35]. Bone metastases are present in up 66% of patients
in some studies, mostly in the transverse skeleton as in thoracic spine, lumbosacral spine,
sacrum. Frequently they can also be present in ribs, skull, head of femur and peripheral bones
[24,32]. Rarely HCC can have as only presentation pain or other symptoms caused by bone
metastases, and this can also occur in non-common bone sites [36,37].
HCC metastases can cause also symptoms linked to nervous system. In fact in case of vertebral
fractures, spinal cord compression can occur, causing neurological symptoms, leading to
paraplegia in some cases. Clinical features of spinal compression can occur as complication of
advanced known HCC, or rarely they can be the clinical presentation of this tumor [38].
Excluding lymph nodes, lung is the most common site of metastases (54% of metastatic HCC)
[39].Lung metastases sometimes are causes of dyspnea, cough, hemoptysis, chest pain [40].
Fatal respiratory failure is described in more or less 20% of HCC lung metastatic tumors [39].
Brain metastases are not frequent, but often they cause important neurological symptoms, up
to causing paralysis in most of these cases [39].
Peritoneal metastases can cause ascites and abdominal pain and they are present in more or
less 10% of metastatic HCC [32]. Rarely, metastases were reported in appendix, and signs and
symptoms typical of acute appendicitis, as pain in the right lower quadrant associated with
tenderness at the physical examination, can be a clinical presentation of HCC [41].
6. Paraneoplastic syndromes
Paraneoplastic syndromes occur in 19-44% of patients affected by HCC [42,43]. The presence
of paraneoplastic syndromes is described to be related with younger patients, with larger size
tumor (>10 cm) and with presence of portal vein thrombosis [43].
Among patients that have paraneoplastic syndromes during the clinical course of HCC, most
of them have a single paraneoplastic manifestation. Hypercholesterolemia, erythrocytosis,
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hypoglycemia and hypercalcemia are some of the most common paraneoplastic manifestations
of HCC. Only 7% of patients have 2 of these syndromes, and rarely can be present all of them
(<1% of cases) [42].
Below, there are described the most common paraneoplastic syndromes and there are also
reported other manifestations described in some case reports. See (Table 3) for some of the
reported paraneoplastc syndromes.
6.1. Hypoglycemia
Hypoglycemia is not an infrequent paraneoplastic syndrome caused by HCC, occurring in
about 4,6-27% of the patients with advanced HCC [43–45]. Hypoglycemia is caused by the
increased demand for glucose by the tumor together with a reduction of gluconeogenesis and
glycogenolysis, due to a decreased residual liver tissue coupled with cachectic state and
malnutrition that are often present in these patients [46]. Episodes of hypoglycemia caused by
an advanced HCC typically occur in the last weeks before the death of the patients.
Another pathologic mechanism involved in causing hypoglycemia is overproduction by the
tumor of Insulin-Like Growth Factor II [47]. Hypoglycemia caused by over production of IGF
II occurs not only in late stage HCC, but also in the early phases of the neoplastic disease [44].
Hypoglycemia has been also described as the first clinical manifestation of HCC in some
reports [44,48].
6.2. Hypercalcemia
Hypercalcemia is described to occur in 7-12% of patients with HCC [43,45,49]. A PTH-like
humoral factor is probably responsible of this paraneoplastic syndrome [50]. Hypercalcemia
can also be caused by the presence of osteolytic bone metastases [51].
Frequency of metastases in different sites (%)
Frequent Sites Not Frequent Sites
Lungs 55 Brain 2
Lymph Nodes 53 Rectum 1
Regional 41 Spleen 1
Distant 12 Diaphragm 1
Musculoskeletal 28 Duodenum 1
Adrenal 11 Esophagus 1
Peritoneum and/or omenutm 11 Pancreas 1
Seminal Vescicle 1
Bladder 1
Table 2. [32]
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Hypercaclemic coma can occur in patients with HCC and it can be confused with hepatic
encephalopathy [52].
6.3. Hypercholesterolemia
Paraneoplastic hypercholesterolemia is present in 11-20% of patients with HCC [43,45,53].
Hypercholesterolemia in patients with HCC has been related with a reduced expression of
LDL receptor, as in familiar hypercholesterolemia. Clinical manifestation of hypercholestero‐
lemia in patients with HCC are not reported, but increased cardiovascular risk can be present
and manifestations typical of familiar hypercholesterolemia, as xanthelasmas could be
possible.
6.4. Erythrocytosis
Erythrocytosis is present in 2-16% of patients with HCC [45,54–58]. Higher levels of erythro‐
poietin, produced by the tumor, have been reported [58]. Local hypoxia has been suggested
to be the cause of overproduction of erythropoietin by large HCC tumors [58,59].
Erythrocytosis accompanied by high levels of erythropoietin has been described as a rare
primary presentation of HCC [60].
6.5. Thrombocytosis
Thrombocytosis has been reported to be present in 3% of cases of HCC. This paraneoplastic
syndrome seems to occur in younger patients (<60 yr), being related with the presence of a
larger tumor and main portal vein tumor thrombosis representing an unfavorable prognostic
factor [61]. Thrombocytosis has been described to be related with thrombopoietin production
by the HCC [62]. A case of HCC associated with both thrombocytosis and acquired Von
Willebrand disease has been reported [63].
6.6. Arterial hypertension
Arterial hypertension has been described as a paraneoplastic manifestation of HCC. Some
cases of severe arterial blood pressure associated with high plasma level of angiotensin-I,
accompanied with hypokalemia have been reported [64]. Elevated concentrations of angio‐
tensinogen have been found, whether or not associated with higher plasma levels of renin.
Overproduction of angiotensinogen and renin could both play a role in causing paraneoplastic
hypertension in patients affected by HCC [65].
6.7. Diarrhea
Watery diarrhea is another manifestation that can occur in patients with HCC. Overproduction
of intestinal peptides as gastrin and vasoactive intestinal peptide (VIP) is one possible
explanation of the onset of diarrhea in these patients [66]. Diarrhea was also described to be a
possible clinical presentation of HCC [67–69].
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6.8. Feminization
Feminization is described to be present in patient with HCC, also in those not affected by liver
cirrhosis, showing clinical signs and symptoms as gynecomastia, loss of body hair, loss of
libido. Onset of spider naevi can be a sign of an underlying HCC and this finding has been
reported more frequently in men than in women [70]. Studies about circulating sex hormones
in patients affected by HCC have shown unclear results and a direct role of HCC in causing
feminization is still not defined [71–74].
7. Cutaneous manifestaion
Various cutaneous manifestations have been reported as paraneoplastic syndromes caused by
HCC. In rare cases, dermatomyositis has been described in patients affected by HCC, either
associated or not to viral hepatitis. [75–77]. Also polymyositis can be a paraneoplastic mani‐
festation of HCC. Polymyositis has been described also as a rare presenting manifestation of
HCC, sometimes causing severe rhabdomyolysis [78–81].
A relationship between HCC and acquired porphyria cutanea tarda has been reportedin
literature, [82–84].
Pityriasis rotunda is a rare cutaneous disease characterized by round/oval, hypo/hyperpig‐
mented rash with scaling. The number of skin lesion is variable and the size is described to be
between 1,5 to 25 cm. The localization of the lesions is usually over the trunk, lower back and
proximal extremities [85,86].
In South African Black patients with diagnosis of HCC, its prevalence is of 16%, much higher
than in patients affected by other diseases associated with pityriasis rotunda. In selected
groups of people, the onset of this cutaneous disorder could represent a diagnostic instrument
for HCC [87].
The sign of Leser-Trelat defined as the abrupt appearance and rapid increase in size and
number of multiple seborrheic keratoses as a result of cancer development has been reported
[88]. This sign has been reported also in association to HCC [89].
Also paraneoplastic pemphigus has been related to HCC [90].
8. Neurological manifestations
Neurologic paraneoplasic syndromes are rarely present in patients affected by HCC, such as
multifocal necrotizing leukoencephalopathy leading to coma or non-inflammatory cerebral
vasculopathy with widespread cortical and subcortical infarcts causing progressive hemipa‐
resis and dysarthria, also in young patients [91,92].
Peripheral polyneuropathy with cranial nerve involvement has been described as a rare
presenting manifestation of HCC [93].
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9. Other paraneoplastic syndromes
Other paraneoplastic manifestations rarely described in patients with HCC are dysfibrino‐
gennemia [94,95], cryofibrinogenemia [96], carcinoid syndrome [24], myasthenia gravis [97]
and membranous glomerulonephritis [98].
Paraneoplastic Syndromes
Usual Manifestations
Hypoglycemia Hypercalcemia Hypercholesterolemia Erythrocytosis
Thrombocytosis Pityriasis Rotunda
Reported Manifestations
Arterial Hypertension Dermatomyositis/Polymyositis Porphyria cutanea tarda Pemphigus
Sign of Leser-Trelat Diarrhea Neurological manifestations Membranousglomerulonephritis
Dysfibrinogenemia Cryofibrinogenemia Carcinoid syndrome Myasthenia grave
Table 3. Add caption
10. Conclusion
Clinical signs and symptoms of HCC are various. In absence of screening programs clinical
signs can be helpful for diagnosis. Clinical signs are different depending on tumor size,
vascular invasion, presence of cirrhosis and presence of metastases. Several paraneoplastic
syndromes are described but our knowledge about some manifestation is limited to few
published case reports.
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